全文获取类型
收费全文 | 2230篇 |
免费 | 165篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 124篇 |
妇产科学 | 15篇 |
基础医学 | 180篇 |
口腔科学 | 51篇 |
临床医学 | 264篇 |
内科学 | 606篇 |
皮肤病学 | 28篇 |
神经病学 | 141篇 |
特种医学 | 269篇 |
外科学 | 137篇 |
综合类 | 31篇 |
预防医学 | 180篇 |
眼科学 | 127篇 |
药学 | 64篇 |
中国医学 | 7篇 |
肿瘤学 | 173篇 |
出版年
2023年 | 27篇 |
2022年 | 10篇 |
2021年 | 29篇 |
2020年 | 17篇 |
2019年 | 32篇 |
2018年 | 55篇 |
2017年 | 25篇 |
2016年 | 38篇 |
2015年 | 38篇 |
2014年 | 49篇 |
2013年 | 53篇 |
2012年 | 67篇 |
2011年 | 61篇 |
2010年 | 55篇 |
2009年 | 77篇 |
2008年 | 76篇 |
2007年 | 68篇 |
2006年 | 61篇 |
2005年 | 60篇 |
2004年 | 64篇 |
2003年 | 62篇 |
2002年 | 63篇 |
2001年 | 57篇 |
2000年 | 57篇 |
1999年 | 48篇 |
1998年 | 54篇 |
1997年 | 60篇 |
1996年 | 69篇 |
1995年 | 56篇 |
1994年 | 49篇 |
1993年 | 57篇 |
1992年 | 46篇 |
1991年 | 81篇 |
1990年 | 59篇 |
1989年 | 81篇 |
1988年 | 63篇 |
1987年 | 67篇 |
1986年 | 76篇 |
1985年 | 71篇 |
1984年 | 51篇 |
1983年 | 23篇 |
1982年 | 32篇 |
1981年 | 18篇 |
1980年 | 14篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1977年 | 20篇 |
1976年 | 21篇 |
1975年 | 17篇 |
1971年 | 9篇 |
排序方式: 共有2406条查询结果,搜索用时 31 毫秒
1.
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure 总被引:1,自引:0,他引:1
STUDY OBJECTIVE: To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in patients with severe chronic heart failure. DESIGN: Unblinded, before-after study. SETTING: Referral center for patients with heart failure. PATIENTS: Thirty patients with severe chronic heart failure and a left ventricular ejection fraction less than 40%. INTERVENTIONS: Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide. MEASUREMENTS AND MAIN RESULTS: Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min.m2 body surface (mean change 0.5 +/- 0.1; P less than 0.001), a fall in stroke work index from 26 to 18 g.m/m2 (mean change 8 +/- 2; P less than 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 +/- 2; P less than 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients. CONCLUSIONS: Encainide can cause adverse hemodynamic and clinical effects in patients with severe chronic heart failure. 相似文献
4.
Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure 总被引:4,自引:0,他引:4
Renal function was evaluated in 104 patients with severe chronic heart failure whom we treated with captopril or enalapril. Seventy patients showed no change or an improvement in renal function (group A), and 34 patients developed functional renal insufficiency (group B). Before converting-enzyme inhibition, group B patients received higher doses of furosemide (p less than 0.02) and had lower central venous pressures (p less than 0.05) than group A patients. After 1 to 3 months of converting-enzyme inhibition, an excessive reduction in left ventricular filling pressure (to less than 15 mm Hg) or mean arterial pressure (to less than 60 mm Hg) was noted in 28 of 34 (82%) patients in group B but in only 22 of 70 patients in group A (31%) (p less than 0.001). At the end of the study, drug-induced azotemia resolved after a reduction in the dosage of diuretics, despite unaltered treatment with captopril and enalapril. Hence, the deterioration of renal function after converting-enzyme inhibition in heart failure is not a toxic or immunologic reaction to therapy but results from specific hemodynamic events that can be ameliorated by sodium repletion. 相似文献
5.
6.
7.
8.
9.
10.